u/aurel_mwangi

Pushback: you changed the dose, the meal timing and the training in the same fortnight, so the attribution is guesswork.

Where a supplier holds regional stock, the shipment is domestic and there is no import event at all. That is the structural fix rather than a workaround.

Gently disagree with the framing — nothing has gone wrong. Week 13 looking flat is the ordinary experience.

Shipped from regional stock or from origin?

Been at maintenance for 20 months on 2.5mg. Nothing happens. That is the whole report and it took me a while to accept it as success.

monthly weigh-ins are enough at this stage

Research-use-only material is not approved for human use. That is a plain statement of regulatory fact and it belongs in every beginner thread.

Small fix — that was the cardiovascular outcomes trial, so weight was a secondary endpoint and the population was different.

Date of analysis anchors the result to a manufacturing period. A two-year-old result is evidence about two years ago and should be read that way.

Is the goal weight still the one you picked at the start?

the habits are the part that has to outlive the dose

discontinuation rate is a result, not a footnote

Push back on the advice above: nobody here can tell a member what dose to take, however confidently it is phrased.

Correction: the starting dose is a tolerance step rather than a treatment dose. The distinction is the answer to the question above.

That service reports area percent by default. Worth stating, since the thread has been comparing it to a mass figure.

Which service, and did you pay for it yourself?

Cardiovascular outcome trials are powered for events, not for weight, and are typically run in a different population with different inclusion criteria. Reading a weight number out of one is reading a secondary endpoint.

Has anything else changed in the same window?

Yes — the day-two-to-day-four window is so consistent across this board that it is almost diagnostic.

Inter-lab variance on this assay runs roughly a point either way, driven mostly by gradient and integration. Two results inside that band agree; they do not disagree quietly.

Not convinced by the comparison. Different services, different gradients, and you are treating one as ground truth.

The effect on gastric emptying is most pronounced early and attenuates with continued dosing, which is the mechanism behind the "it settles at a stable dose" pattern the whole board reports.